knowledge -WSS

knowledge

author：hotspot 2025-09-02 11:43:46 - browse：23

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： New brain studies show LSD's effects on the brain in full color

WSS

Will the market for weight loss drugs really reach $100 billion?

Pediatric cancer treatments threatened by a new FDA policy

FDA clears AI tool for detecting skin cancer

Dewpoint Therapeutics lays off staff after losing partnerships

Elizabeth Holmes banned from government health programs

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

hotspot

knowledge

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

EU regulator recommends expanding Mounjaro approval to obesity

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Mayo Clinic plans $5B tech

As demand for Covid shots wanes, Moderna seeks its next success

Elizabeth Holmes banned from government health programs

New air purifier tech could be key to improving indoor air quality

Rep. Raul Ruiz on the physician shortage and more

Hepatitis C has a cure — but many Americans still lack access to it

30 years of 'Listening to Prozac'

focus

Organ aging and disease risk measured by new blood test

With clinical trial data readouts, here's how to spot spin

Copay coupons to count toward deductibles, after Biden court move

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Will the market for weight loss drugs really reach $100 billion?

How to pay for weight loss drugs and save Medicare

Wikipedia

focus

hotspot

knowledge